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Abstract
Background: There is an urgent requirement to identify biomarkers to tailor treatment in human epidermal growth factor
receptor 2 (HER2)–amplified early breast cancer treated with trastuzumab/pertuzumab-based chemotherapy.
Methods: Among the 225 patients randomly assigned to trastuzumab/pertuzumab concurrently or sequentially with an
anthracycline-containing regimen or concurrently with an anthracycline-free regimen in the Tryphaena trial, we deter-
mined the percentage of tumor-infiltrating lymphocytes (TILs) at baseline in 213 patients, of which 126 demonstrated a
pathological complete response (pCR; ypT0/is ypN0), with 28 demonstrating event-free survival (EFS) events. We investi-
gated associations between baseline TIL percentage and either pCR or EFS after adjusting for clinicopathological characteris-
tics using logistic and Cox regression models, respectively. To understand TIL biology, we evaluated associations between
baseline TILs and baseline tumor gene expression data (800 gene set by NanoString) in a subset of 173 patients. All statistical
tests were two-sided.
Results: Among the patients with measurable TILs at baseline, the median level was 14.1% (interquartile range ¼ 7.1%–32.4%).
After adjusting for clinicopathological characteristics, baseline percentage TIL was not associated with pCR (adjusted odds
ratio [aOR] for every 10-percentage unit increase in TILs ¼ 1.12, 95% confidence interval [CI] ¼ 0.95 to 1.31, P ¼ .17). At a
median follow-up of 4.7 years, for every increase in baseline TILs of 10%, there was a 25% reduction in the hazard for an EFS
event (aOR ¼ 0.75, 95% CI ¼ 0.56 to 1.00, P ¼ .05) after adjusting for baseline clinicopathological characteristics and pCR.
Additionally, genes associated with epithelial-mesenchymal transition, angiogenesis, and T-cell inhibition such as SNAIL1,
ZEB1, NOTCH3, and B7-H3 were statistically significantly inversely correlated with percentage TIL.
Conclusions: Baseline TIL percentage provides independent prognostic information in patients treated with trastuzumab/
pertuzumab-based neoadjuvant chemotherapy. However, further validation is required.
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The percentage of stromal tumor-infiltrating lymphocytes
(TILs) was associated with an increased pathological complete
response (pCR) rate in patients with human epidermal growth
factor receptor 2 (HER2)–amplified breast cancer receiving either
neoadjuvant anthracycline and taxane-based chemotherapy
alone in the GeparDuo and GeparTrio trials (1) or weekly pacli-
taxel with trastuzumab or lapatinib or both in the NeoALTTO
trial (2). Similarly, high expression of immune-related genes/
gene signatures was associated with increased pCR rates in
patients who received neoadjuvant anthracycline and taxane-
based chemotherapy alone (3) or weekly paclitaxel in combina-
tion with trastuzumab and lapatinib (4). In the Neosphere trial
(randomizing patients between trastuzumab plus docetaxel vs
trastuzumab/pertuzumab plus docetaxel vs trastuzumab/pertu-
zumab without chemotherapy vs pertuzumab plus docetaxel),
TIL percentage as a continuous variable was not associated
with pCR (5).
However, TIL percentage as a continuous variable (10% in-
crease in level of TILs) was associated with improved distant re-
currence–free survival in the adjuvant trastuzumab arm of the
Finher Trial (6). Furthermore, TIL percentage as a continuous
variable was associated with improved event-free survival (EFS)
in the NeoALTTO trial (2). However, in the pivotal N9831
Adjuvant Trial, TIL percentage as a continuous variable (10% in-
crease in level of TILs) was not associated with a recurrence-free
interval in the trastuzumab arm (7).
No data are available for the prognostic associations of TILs
with pCR and EFS in patients with early breast cancer receiving
standard neoadjuvant chemotherapy (anthracycline/taxane or
carboplatine/taxane) with dual HER2 blockade with trastuzu-
mab and pertuzumab. We aimed to study these associations in
the context of the TRYPHAENA neoadjuvant study (8).
Methods
TRYPHAENA Study Design
The TRYPHAENA study (NCT00976989) design and results have
been previously reported (8) and are described in the
Supplementary Methods (available online). Written informed
consent was obtained from each participant. Approval for the
protocol and for any modifications was obtained from indepen-
dent ethics committees (committees are listed in the
Supplementary Methods, available online).
Stromal Tumor-Infiltrating Lymphocyte Evaluation
The percentages of stromal coverage by TILs (hereafter referred
to as TIL percentage) before (at diagnosis) and after (for patients
with residual invasive breast cancer) dual HER2 blockade were
evaluated in hematoxylin and eosin (H&E) slides from diagnos-
tic biopsies and surgical samples from patients enrolled in the
TRYPHAENA study. TIL percentage at surgery was evaluated in
patients with residual invasive breast cancer. In the analyses,
the geometric means of the percentage of TILs present were de-
termined by two independent pathologists (9); the agreement
between the two pathologists was evaluated as explained in the
Supplementary Methods (available online). TIL percentage at di-
agnosis was assessed according to the 2014 guidelines devel-
oped by the International Immuno-Oncology Biomarker
Working Group (10). TIL percentage for patients with residual
invasive disease was scored according to guidelines developed
by the International Immuno-Oncology Biomarker Working
Group (11). In cases of pCR or if no tumor bed could be identi-
fied, TIL assessment was not performed.
Gene Expression Using the NanoString nCounter Assay
Sample processing and RNA extraction for gene expression pro-
filing are described in the Supplementary Methods (available
online). Gene expression data from the NanoString nCounter
assay (previously reported custom designed 800-gene panel
tailored for breast cancer [12]) were analyzed after quality
control filtering and normalization using the R package
NanoStringQCPro (version 0.99.8.3). As recommended, the mean
of the positive probes and the housekeeping genes were used in
order to account for differences in sample input. Moreover, neg-
ative control probes were used for background correction, and
samples that did not pass quality control were removed. Raw
and normalized NanoString data have been deposited in the
Gene Expression Omnibus database under accession number
GSE109710.
We calculated the expression of the ERBB2 and ESR1, genes
that have been shown to be associated with pCR after neoadju-
vant chemotherapy and anti-HER2 agents (4,13), and the expres-
sion of well-known genes associated with CD8þ T-cell cytolytic
activity: granzyme A and B (GZMA and GZMB) and perforin 1
(PRF1), with T-regulatory cells: forkhead box P3 (FOXP3), with
immune checkpoint inhibition: cytotoxic T-lymphocyte-associ-
ated protein 4 (CTLA4), programmed death–ligand 1 (PDL1) and
programmed cell death protein 1 (PD1), with T-helper pheno-
type 1: interferon-gamma (IFNG) and 2: interleukin 4 (IL4).
Moreover, we computed three immune-gene signatures, a
STAT1-related gene signature (immune_STAT1) (14), a signature
related to the presence of tertiary lymphoid structures
(immune_TLS) (15), and an immune-gene signature associated
with benefit from adjuvant trastuzumab in the North Central
Cancer Treatment Group N9831 adjuvant trastuzumab trial
(immune_trastuzumab) (16). Details about single gene/signature
scores calculations and PAM50 subtype definition are provided
in the Supplementary Methods (available online).
Statistical Analyses
The association between TIL percentage, at baseline and at re-
sidual disease or surgery, with clinicopathologic variables was
evaluated using linear regression. Clinicopathological variables
included age (<50 and 50 years), histology grade (III vs I/II), es-
trogen receptor (ER) status (positive vs negative), clinical stage
(III vs II), and chemotherapy (anthracyclines vs nonanthracy-
clines). The dependence of pCR, defined as absence of invasive
tumor in the breast and lymph nodes (ypT0/is ypN0), on TIL
percentage at baseline and clinicopathologic variables was
assessed using logistic regression models.
The presence of nonlinear effects of TIL percentage at base-
line on pCR probability on the logit scale, modeled by restricted
cubic splines, was evaluated by Wald test. pCR probabilities
according to TIL quartiles at baseline were also estimated, with
95% confidence intervals (CIs) computed by the Wilson method.
EFS was defined as the time from the date of surgery to the first
documentation of disease progression or death. Any evidence
of contralateral disease in situ was not considered disease pro-
gression. EFS was described separately in patients who achieved
a pCR from those who did not. Patients who were withdrawn
from the study without documented disease progression were
censored at the date of the last assessment when the patient
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was known to be disease-free. Median follow-up was obtained
by the reverse Kaplan-Meier method. Association of EFS with
TIL percentage and clinicopathological variables was examined
using the Cox regression model. All tests of statistical signifi-
cance were two-sided, and a P value of less than .05 was consid-
ered statistically significant.
Statistical analysis of gene expression data generated
using the NanoString nCounter Assay is described in the
Supplementary Methods (available online). This study has been
reported according to the Reporting Recommendations for
Tumor Marker Prognostic Studies (REMARK) criteria (17).
Results
Patient Characteristics
The patient characteristics for the entire TRYPHAENA cohort,
the subgroups of patients with evaluable TILs at baseline and at
the point of surgery, and available gene expression data at base-
line are summarized in Table 1. TIL status was successfully
evaluated in 213 (94.7%) of 225 patients at baseline and in 64
(73.6%) of 87 patients with invasive residual disease at the point
of surgery. The reasons behind unsuccessful evaluation are pre-
sented in the CONSORT diagram for TILs (Supplementary Figure
1, available online). The main reason for missing results at the
point of surgery was either because patients had pCR or because
the pathologists were not able to identify the tumor bed in
available H&E slides (n ¼ 140 patients) (Supplementary Figure 1,
available online). Agreement between the two pathologists was
good (Supplementary Figure 2, available online). For Log TILs
at baseline, the concordance correlation coefficient was
0.62 (95% CI ¼ 0.55 to 0.68), while at surgery it was 0.66 (95% CI ¼
0.59 to 0.73).
The expression of immune-related single genes and gene
signatures at baseline in tumor samples was successfully evalu-
ated using NanoString technology in 173 of 225 (76.9%) patients.
A lack of sample was the main reason for missing data (n ¼ 41),
with additional reasons described in the CONSORT diagram for
NanoString gene expression data (Supplementary Figure 3,
available online).
TIL Percentage at Baseline and Baseline
Clinicopathological Characteristics
We first tested whether there was any association between TIL
percentage and clinicopathological characteristics at baseline.
No evidence of association was found between TIL percentage
and age, ER status, or type of neoadjuvant chemotherapy
(anthracycline-based vs other) (Supplementary Table 1, avail-
able online). However, there was an association between an in-
creased TIL percentage at baseline and histological grade III
tumors (P ¼ .03).
TIL Percentage at Baseline and pCR
No evidence for a nonlinear relationship between pCR probabil-
ity on the logit scale and TIL percentage at baseline was found.
Figure 1 and Supplementary Figure 4 (available online) depict
pCR rates according to TIL percentage at baseline assessed as a
categorical variable using quartiles and a scatterplot of pCR
Table 1. Patient characteristics
Variable
All patients
No. (%)
Patients with evaluable
TILs* at baseline
No. (%)
Patients with evaluable
TILs at surgery and
no pCR
No. (%)
Patients with available
gene expression data at
baseline
No. (%)
Total 225 (100.0) 213 (100.0) 64 (100.0) 173 (100.0)
Age, y
<50 112 (49.8) 108 (50.7) 41 (64.1) 89 (51.4)
50 113 (50.2) 105 (49.3) 23 (35.9) 84 (48.6)
Histology grade
I/II 101 (56.4) 95 (55.2) 36 (66.7) 74 (52.9)
III 78 (43.6) 77 (44.8) 18 (33.3) 66 (47.1)
Unknown 46 41 10 33
Estrogen receptor*
Negative 118 (52.7) 112 (52.6) 20 (31.7) 94 (54.3)
Positive 106 (47.3) 101 (47.4) 43 (68.3) 79 (45.7)
Unknown 1 – 1 –
Clinical stage†
II 115 (51.6) 110 (52.1) 27 (42.2) 92 (53.5)
III 108 (48.4) 101 (47.9) 37 (57.8) 80 (46.5)
Unknown 2 2 – 1
Chemotherapy
Non-anthracycline-based 77 (34.2) 72 (33.8) 17 (26.6) 59 (34.1)
Anthracycline-based 148 (65.8) 141 (66.2) 47 (73.4) 114 (65.9)
pCR (ypT0/is ypN0)
No 94 (41.8) 87 (40.8) 64 (100.0) 70 (40.5)
Yes 131 (58.2) 126 (59.2) – 103 (59.5)
EFS, No. of events 29 28 14 26
*Estrogen receptor status evaluated using immunohistochemistry. EFS ¼ event-free survival; pCR ¼ pathological complete response; TILs ¼ tumor-infiltrating
lymphocytes.
†Clinical stage assessed using the 7th edition of the American Joint Committee on Cancer Staging.
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rates across several TIL percentage cutoffs, respectively. In a
univariate analysis, TIL percentage at baseline was not signifi-
cantly associated with pCR (odds ratio [OR] ¼ 1.15, 95% CI ¼ 0.99
to 1.32, P ¼ .06) (Table 2). In this study, among other baseline
clinicopathological characteristics, only ER status was signifi-
cantly associated with pCR, with ER-positive tumors having a
lower probability for pCR (OR ¼ 0.32, 95% CI ¼ 0.19 to 0.56, P <
.001) (Table 2). In a multivariable model including baseline clini-
copathological characteristics and percentage TILs, TILs were
not significantly associated with pCR (OR for every 10-percent-
age unit increase in TILs ¼ 1.12, 95% CI ¼ 0.95 to 1.31, P ¼ .17)
(Supplementary Table 2, available online). Only ER-positive and
higher–clinical stage tumors were independently associated
with a lower probability of pCR.
TIL Percentage at Baseline and EFS
Next, we investigated whether there was association between
TILs at baseline and EFS. After a median follow-up of 4.7 years,
for every 10% increase in TILs at baseline, EFS increased, but
this change was not statistically significant, with a hazard ratio
(HR) of 0.80 (95% CI ¼ 0.63 to 1.02, P ¼ .08) (Table 2). When we ex-
amined associations between baseline clinicopathological char-
acteristics and EFS, a higher clinical stage was associated with a
shorter EFS (HR ¼ 2.45, 95% CI ¼ 1.11 to 5.42, P ¼ .03), whereas
the presence of pCR was associated with longer EFS (HR ¼ 0.35,
95% CI ¼ 0.16 to 0.73, P ¼ .005) (Table 2). In a multivariable model
including baseline clinicopathological characteristics, baseline
TIL percentage, and pCR, only pCR and baseline TIL percentage
were independently associated with EFS (Table 3). In this model,
for every 10-percentage unit increase in baseline TILs, there was
a 25% reduction in the hazard for the event (adjusted HR ¼ 0.75,
95% CI ¼ 0.56 to 1.00, P ¼ .05). Interestingly, when we examined
the EFS of patients according to the presence of pCR (yes vs no)
and the level of percentage TIL (high vs low based on the me-
dian TIL value of 14.1% [interquartile range ¼ 7.1%–32.4%] in
this series), we found that patients with high baseline percent-
age TIL and pCR had the best prognosis compared with the
other groups (Figure 2). No evidence of interaction between pCR
and baseline TIL percentage, dichotomized with cutoff of 14%,
was observed (P ¼ .10).
TIL Percentage at the Point of Surgery
TIL percentage at the point of surgery was evaluated in 64 of 87
patients with invasive residual disease (Supplementary Figure
1, available online). TILs at surgery were not significantly associ-
ated with baseline clinicopathological characteristics
(Supplementary Table 3, available online), or with EFS (HR ¼
1.05, 95% CI ¼ 0.73 to 1.50, P ¼ .80) (Table 2), although the small
number of patients and events does not allow definitive conclu-
sions to be drawn.
Figure 1. Pathological complete response rates by tumor-infiltrating lymphocyte (TIL) quartiles at baseline, assessed as a categorical variable. The error bars represent
95% confidence intervals, computed according to the Wilson method. pCR ¼ pathological complete response; TIL ¼ tumor-infiltrating lymphocyte.
Table 2. Univariate associations between variables and pathologic complete response and event-free survival
Variable
Univariate for pCR* Univariate for EFS
No. of patients
(pCR event) OR (95% CI) P*
No. of patients
(EFS event) HR (95% CI) P†
Age: 50 vs <50 y 225 (131) 1.47 (0.86 to 2.50) .16 208 (29) 1.54 (0.74 to 3.23) .25
Histology grade: III vs I/II 179 (101) 1.59 (0.87 to 2.91) .13 166 (26) 0.71 (0.31 to 1.58) .40
Estrogen receptor: positive vs negative 224 (131) 0.32 (0.19 to 0.56) <.001 207 (29) 0.94 (0.45 to 1.94) .86
Clinical stage: III vs II 223 (130) 0.64 (0.38 to 1.10) .11 207 (28) 2.45 (1.11 to 5.42) .03
Chemotherapy: anthracycline-based vs not 225 (131) 0.71 (0.40 to 1.25) .24 208 (29) 0.83 (0.39 to 1.76) .63
Baseline TILs (10-unit increase) 213 (126) 1.15 (0.99 to 1.32) .06 198 (28) 0.80 (0.63 to 1.02) .08
TILs at surgery‡ (10-unit increase)    63 (14) 1.05 (0.73 to 1.50) .80
pCR: yes vs no    208 (29) 0.35 (0.16 to 0.73) .005
*P values based on two-sided Wald tests from univariate logistic regression models. CI¼ confidence interval; EFS ¼ event-free survival; HR ¼ hazard ratio; OR¼ odds ra-
tio; pCR ¼ pathologic complete response; TILs ¼ tumor-infiltrating lymphocytes.
†P values based on two-sided Wald tests from univariate Cox regression models.
‡Patients with no pCR.
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Association Between TIL Percentage at Baseline and
Gene Expression (NanoString) in Baseline Tumor
Samples
In the 173 patients for whom baseline tumor gene expression
data were available, we found that TIL percentage at baseline
strongly correlated with most immune genes and gene signa-
tures, but not with ESR1 or ERBB2 (Figure 3). No association was
found between TIL percentage and the PAM50 intrinsic subtype
(Kruskal-Wallis P ¼ .48) within HER2 breast cancer patients
(Supplementary Figure 5, available online). To derive further
insights into the tumor biology associated with an immune re-
sponse as measured by TIL percentage, we evaluated associa-
tions between TIL percentage at baseline and more than 800
cancer-related genes (Figure 4A). Interestingly, gene ontology
analysis showed that TIL percentage was statistically
significantly inversely correlated with genes associated with ep-
ithelial mesenchymal transition (EMT), angiogenesis, and T-cell
inhibition (Figure 4B), such as SNAIL1, ZEB1, NOTCH3, and B7-H3
(Figure 4C).
Gene Expression (NanoString) in Baseline Tumor
Samples and pCR
Next, we investigated the association between pCR and the
baseline expression of the following: single genes (ESR1, ERBB2),
the PAM50 subtype (HER2-enriched subtype vs others), three
immune-related gene signatures, and single immune-related
genes (GZMA and GZMB, PRF1, FOXP3, CTLA4, PDL1, PD1, IL4,
IFNG). After correction for multiple testing, increased pCR rates
were observed in patients with a HER2-enriched subtype, higher
expression of ERBB2, the immune_TLS and immune_trastuzu-
mab gene signatures, and GZMA and GZMB, PRF1, PD1 and IFNG
in a univariate analysis (Supplementary Figure 6, available on-
line). Following multivariable analysis (after adjustment for
baseline clinicopathological characteristics and baseline TILs)
and correction for multiple testing, increased pCR rates were
observed in patients with a higher expression of ERBB2,
immune_TLS and immune_trastuzumab gene signatures, and
GZMA and GZMB, PRF1 and IFNG (Figure 5). When we examined
the distribution of pCR rates across PAM50 subtypes
(Supplementary Figure 7, available online), we observed the
highest response (57 out of 82 patients or 69.5%) for the HER2-
enriched subtype (P ¼ .02).
Gene Expression (NanoString) in Baseline Tumor
Samples and EFS
There was no association between EFS and the expression of any
of the immune genes/gene signatures tested (Supplementary
Figure 8, available online). In a multivariable analysis includ-
ing baseline clinicopathological characteristics, PAM50 sub-
type, pCR, and baseline TIL percentage, pCR remained
statistically significantly associated with EFS (P ¼ .02) but not
with TIL percentage (P ¼ .06) (Supplementary Table 4, available
online).
Discussion
To our knowledge, this is the first study to evaluate associations
between TIL percentage at baseline, pCR, and EFS following neo-
adjuvant chemotherapy and dual HER2 blockade with trastuzu-
mab and pertuzumab in HER2-amplified early breast cancer. We
provide for the first time evidence that TIL percentage at base-
line and pCR provide independent prognostic information for
EFS in patients treated with trastuzumab/pertuzumab-based
neoadjuvant treatment. For every 10% increase in the level of
baseline TILs, there was a 25% reduction in the occurrence of
EFS events. These results need further validation in an indepen-
dent patient cohort. Patients with a high baseline TIL percent-
age (14%) and pathological complete response had an
excellent prognosis following neoadjuvant chemotherapy and
dual HER2 blockade with trastuzumab and pertuzumab. Similar
results to this association between baseline TIL percentage,
pCR, and EFS for the trastuzumab and lapatinib combination
have been reported in the NeoALTTO trial (2).
The results of our study may have clinical implications for
tailoring treatment in patients with HER2-amplified early breast
cancer. For example, in 2013, pertuzumab was approved in
Table 3. Multivariable Cox regression (No. of patients included in the
model ¼ 159, No. of patients with EFS event ¼ 24)
Variable HR (95% CI) P*
Age: 50 vs <50 y 1.37 (0.60 to 3.13) .46
Histology grade: III vs I/II 1.21 (0.47 to 3.07) .70
Estrogen receptor: positive vs negative 0.72 (0.30 to 1.73) .46
Clinical stage: III vs II 1.89 (0.79 to 4.51) .15
Chemotherapy: anthracycline-
based vs not
0.52 (0.22 to 1.22) .13
pCR: yes vs no 0.22 (0.08 to 0.61) .004
Baseline TILs (10-unit increase) 0.75 (0.56 to 1.00) .05
*P values based on two-sided Wald tests from a multivariable Cox regression
model including age, histology grade, estrogen receptor status, clinical stage,
chemotherapy, pCR, and baseline TILs. CI¼ confidence interval; EFS ¼ event-free
survival; HR ¼ hazard ratio; OR¼ odds ratio; pCR ¼ pathologic complete re-
sponse; TILs ¼ tumor-infiltrating lymphocytes.
Figure 2. Kaplan-Meier event-free survival curves of patients according to path-
ological complete response (pCR) status (yes vs no) and tumor-infiltrating lym-
phocytes (TILs) at baseline (>14% vs 14%). Patients were divided into four
groups: TILs >14% and pCR, TILs >14% and non-pCR, TILs 14% and pCR, TILs
14% and non-pCR. pCR ¼ pathological complete response; TIL ¼ tumor-infil-
trating lymphocyte.
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combination with trastuzumab and docetaxel as a neoadjuvant
treatment in patients with HER2-amplified breast cancer (18).
Recently, the Aphinity trial demonstrated that pertuzumab,
when added to trastuzumab as an adjuvant treatment, im-
proved invasive disease–free survival by 1% (19). Due to the
marginal benefit of the Aphinity trial, there is an urgent need to
identify the patient subgroup that can derive most benefit from
the addition of pertuzumab. For Aphinity, the subgroups prede-
fined by clinic-pathological factors that derived the highest ben-
efit were patients with node-positive disease and/or hormone
receptor–negative disease (19); the latter was also seen in the
Tryphaena study. If the results of our trial on the association be-
tween TIL percentage, pCR, and EFS are further confirmed in
other studies or patient cohorts that have received neoadjuvant
pertuzumab-based treatment, one might consider adding pertu-
zumab in high-risk HER2-positive patients as part of neoadju-
vant treatment, as in the Tryphaena trial. Thus, in patients with
a high baseline level of TIL percentage that achieve pCR after
neoadjuvant chemotherapy and dual HER2 blockade with tras-
tuzumab and pertuzumab, trastuzumab alone as adjuvant
treatment might be the appropriate treatment due to the very
good prognosis for this group. In the other patient subgroups,
further clinical research is needed to identify optimal
approaches that might further improve outcome (eg, evaluate
the role of immunotherapy in this setting).
In our study, there was no association between TIL percent-
age at the point of surgery where residual invasive disease was
present and EFS. However, our study was largely underpowered
to detect such associations. In patients with triple-negative
breast cancer (TNBC) receiving neoadjuvant chemotherapy, the
presence of high levels of TILs (>60%) in residual invasive dis-
ease was associated with improved EFS compared with patients
with low levels of TILs (20). More studies with adequate sample
size are needed to evaluate whether such an association exists
in HER2-positive breast cancer. Moreover, it is not known
whether patients with TILs at residual invasive disease might
benefit from immune checkpoint inhibitors. TILs have been as-
sociated with a response to the immune checkpoint inhibitor
pembrolizumab in metastatic TNBC (21). It has also been sug-
gested that the mutational load (22), the number of neoantigens
(23), and neoantigen heterogeneity (clonal vs subclonal neoanti-
gens) (24) are associated with response to immune checkpoint
inhibitors. Increased clonal neoantigen burden has been associ-
ated with increased benefit from immune checkpoint inhibitors in
lung adenocarcinoma (24). Thus, the information on the presence
of clonal neoantigens but also a more detailed characterization of
the immune landscape (25,26) of residual disease following neo-
adjuvant chemotherapy and dual HER2 blockade might provide
more insight into the subgroup of patients that could benefit from
immunotherapeutic approaches in this setting.
Additionally, we observed higher pCR rates for patients in
the HER2-enriched subtype compared with other subtypes and
for patients with higher ERBB2 mRNA levels, as has been ob-
served in the CALGB 40601 (13) and NeoALTTO (4) studies.
Moreover, we demonstrated that after adjustment for
baseline clinicopathological characteristics and baseline TIL
Figure 3. Heat map reflecting the hierarchical clustering of pairwise correlation between baseline tumor-infiltrating lymphocytes and baseline immune-related single
genes/gene signatures in 173 patients. Cells are colored according to Spearman’s correlation coefficient values, with blue indicating a positive correlation and red indi-
cating a negative correlation.
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percentage and correction for multiple testing, increased pCR
rates were associated with high expression of immune signa-
tures related to tertiary lymphoid structures and a signature as-
sociated with benefit from adjuvant trastuzumab, as well as
with high expression of genes associated with CD8þ T-cell cyto-
lytic activity (GZMA, GZMB, PRF1) and with T-helper phenotype
1 (IFNG). Our results extend previously reported associations be-
tween pCR and IFNG in patients who received anti-HER2 treat-
ment in the context of the Neosphere trial (5). The fact that
immune signatures and single genes were not significantly as-
sociated with EFS in our study can be related to the fact that our
study is underpowered to detect such associations; thus further
studies are needed in this respect.
Furthermore, in order to better understand TIL biology,
we evaluated associations between TIL percentage at base-
line and the expression of 800 genes related to breast can-
cer. As expected, increasing levels of TILs were positively
correlated with immune response genes. Interestingly, TILs
were inversely correlated with the expression of genes asso-
ciated with EMT, angiogenesis, and T-cell inhibition, such as
SNAIL1, ZEB1, NOTCH3, and B7-H3. Our results are in line
with preclinical evidence suggesting that snail-induced EMT
promotes immunosuppression in melanoma (27) and that
mesenchymal stromal cells can suppress the immune re-
sponse (28).
Our study has some limitations. There were only 64 patients
with invasive residual disease and evaluable TILs; thus the
study on the association between TILs at surgery and EFS is
largely underpowered. Additionally, concerning the associa-
tions between baseline TILs and either pCR or EFS, all patients
received dual HER2 blockade; thus, we cannot explore single vs
dual HER2 blockade biomarker questions. However, this is the
first study to explore association of TILs at diagnosis with pCR
and EFS for patients with HER2-positive early breast cancer who
have received standard preoperative chemotherapy with trastu-
zumab and pertuzumab. Moreover, we acknowledge that, cur-
rently, there is not a validated cutoff for low vs high TIL
percentage in this setting. Finally, our gene expression data are
hypothesis-generating and need further validation.
In summary, evaluation of baseline TILs might help tailor
treatment options for high-risk HER2-positive breast cancer
patients who receive neoadjuvant chemotherapy and dual
HER2 blockade with trastuzumab and pertuzumab. Further
studies are needed to validate our results.
Figure 4. A) Heat map reflecting the hierarchical clustering of the statistically significantly correlated genes with baseline tumor-infiltrating lymphocytes (TILs). Two-
sided Spearman correlation was used in the analysis, and correction for multitesting (False Discovery Rate [FDR]) was performed. Only genes with jrhoj .30 and FDR
<0.05 were considered statistically significant. B) Gene ontology analysis of the statistically significantly inversely correlated and positively correlated genes with base-
line TILs. C) Correlation plot for the epithelial-to-mesenchymal transition (EMT) markers with baseline TIL levels. Two-sided Spearman correlation was used in the
analysis. Only genes with P <.05 were considered statistically significant. pCR ¼ pathological complete response; TIL ¼ tumor-infiltrating lymphocyte.
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